Hengrui Medicine boosts employee incentives with share buyback

Jiangsu Hengrui Medicine, a pharmaceutical company, announced it repurchased 250,000 A-shares on November 21, 2025, through the Shanghai Stock Exchange. The average repurchase price for these shares was RMB 59.52 per share, with individual transaction prices ranging from RMB 59.32 to RMB 59.72. The total cost for this single day’s repurchase amounted to RMB 14,879,886. These repurchased shares are intended to be held as treasury shares for an A-share employee stock ownership plan.

The latest repurchase brings the cumulative total of A-shares bought back under the current program to 8,898,700 shares as of November 21, 2025. This represents 0.13% of the company’s total share capital. The aggregate cost for all repurchases under this plan has reached RMB 595,216,300. The highest price paid per share was RMB 70.00, and the lowest was RMB 59.32.

The company initially disclosed the buyback plan on August 21, 2025, with a target amount of RMB 1,000,000,000 to RMB 2,000,000,000. The repurchase window extends from August 20, 2025, to August 19, 2026. This ongoing repurchase activity aligns with the company's objective to use repurchased shares for employee incentive schemes, as approved by the board on August 20, 2025.